Clinical Trial Update: Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating litifilimab (BIIB059) in cutaneous lupus erythematosus with or without systemic lupus erythematosus has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• Litifilimab (litifilimab)

Snippet

Sponsor: Biogen | Conditions: Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2023-05-15